Assess Ovarian Cancer Risk *Prior to Surgery.*
Introducing OVA1®+

What is OVA1®+?

For women with adnexal mass, **OVA1®+** is a reflex process which first performs **OVA1®** and then performs **OVERA®** if the **OVA1®** result is in the *intermediate range*.

Low Risk is <4.4 (Postmenopausal) and <5.0 (Premenopausal) **Intermediate Risk** is 4.4-6.0 (Postmenopausal) and 5.0-7.0 (Premenopausal) **Markedly Elevated Risk** is >6.0 Postmenopausal and >7.0 Postmenopausal

What are the Benefits of OVA1®+?

The combination of **OVA1®** and **OVERA®** helps you further stratify your patients risk of malignancy.

Reduces the falsely elevated rate in the **intermediate range** by

OVER 50%

Maintaining the high rate of detection for risk of malignancy

96% SENSITIVITY[1]

(with clinical assessment)

especially in **early stage** disease and all ethnicities

Provides confidence in negative results with a

98% NEGATIVE[1]

predictive value.

1. Bristow RE, Smith A, Zhang Z, et al., Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol. 2013;128:252-259.

Ova1 plus

ASPIRA WOMEN'S HEALTH

OVA1®+ Biomarkers (OVA1® and OVERA®)

Ova1

OVA1® is an FDA cleared multivariate index assay (MIA) that combines the results of five biomarkers and a proprietary algorithm to provide a malignancy risk index.



- **98% Negative Predictive Value**
- **96% Sensitivity (with clinical assessment)**
- **Guideline support from ACOG, SGO & NCCN**

Overa™

OVERA® is an FDA cleared second generation multivariate index assay (MIA) that combines the results of five biomarkers and a proprietary algorithm to provide a malignancy risk index.



- **OVERA® is performed when the OVA1® result is in the intermediate range**
- **69% Specificity, 91% Sensitivity[2]**
- **Performing OVERA® in this range further stratifies risk and reduces the falsely elevated rate**

2. Coleman RL, Herzog TJ, Chan DW, Munroe DG, Pappas TC, Smith A, Zhang Z, Wolf J. Validation of a Second-generation Multivariate Index Assay for Malignancy Risk of Adnexal Masses. Am J Obstet Gynecol. 2016 Mar 9.

OVA1® should be used in women >18yrs that have a pelvic mass to assess ovarian cancer risk prior to surgical treatment planning. It should be used in combination with clinical assessment and is not a screening test.

Ova1 plus

844.277.4721 • aspirawh.com

ASPIRA WOMEN'S HEALTH™